- Home
- AES vs EXAS Comparison
AES vs EXAS Comparison
Compare AES & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AES
- EXAS
- Stock Information
- Founded
- AES 1981
- EXAS 1995
- Country
- AES United States
- EXAS United States
- Employees
- AES N/A
- EXAS N/A
- Industry
- AES Electric Utilities: Central
- EXAS Medical Specialities
- Sector
- AES Utilities
- EXAS Health Care
- Exchange
- AES Nasdaq
- EXAS Nasdaq
- Market Cap
- AES 10.3B
- EXAS 11.0B
- IPO Year
- AES 1991
- EXAS N/A
- Fundamental
- Price
- AES $14.56
- EXAS $64.82
- Analyst Decision
- AES Hold
- EXAS Strong Buy
- Analyst Count
- AES 10
- EXAS 21
- Target Price
- AES $14.89
- EXAS $69.24
- AVG Volume (30 Days)
- AES 12.7M
- EXAS 2.0M
- Earning Date
- AES 11-04-2025
- EXAS 11-03-2025
- Dividend Yield
- AES 4.84%
- EXAS N/A
- EPS Growth
- AES 8.40
- EXAS N/A
- EPS
- AES 1.28
- EXAS N/A
- Revenue
- AES $12,032,000,000.00
- EXAS $2,939,949,000.00
- Revenue This Year
- AES $1.18
- EXAS $16.68
- Revenue Next Year
- AES $4.58
- EXAS $12.12
- P/E Ratio
- AES $11.27
- EXAS N/A
- Revenue Growth
- AES N/A
- EXAS 12.55
- 52 Week Low
- AES $9.46
- EXAS $38.81
- 52 Week High
- AES $17.37
- EXAS $72.83
- Technical
- Relative Strength Index (RSI)
- AES 56.82
- EXAS 81.05
- Support Level
- AES $13.98
- EXAS $63.05
- Resistance Level
- AES $14.79
- EXAS $62.31
- Average True Range (ATR)
- AES 0.38
- EXAS 1.57
- MACD
- AES -0.05
- EXAS 0.27
- Stochastic Oscillator
- AES 56.59
- EXAS 92.60
About AES The AES Corporation
AES is a global power company that operates in 15 countries. Its generation portfolio totals over 32 gigawatts, including renewable energy (50%), gas (32%), coal (16%), and oil (2%). AES has majority ownership and operates six electric utilities distributing power to more than 2.5 million customers.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.